One-year clinical outcomes of everolimus-versus sirolimus-eluting stents in patients with acute myocardial infarction

Title
One-year clinical outcomes of everolimus-versus sirolimus-eluting stents in patients with acute myocardial infarction
Author(s)
김영조Kang-Yin Chen[Kang-Yin Chen]나승운[나승운]왕 린 [왕 린 ]Youn-Jian Li[Youn-Jian Li]Guang-Ping Li[Guang-Ping Li]Cheol Ung Choi[Cheol Ung Choi]Chang Gyu Pakr[Chang Gyu Pakr]Hong Seog Seo[Hong Seog Seo]Dong Joo Oh[Dong Joo Oh]
Keywords
CORONARY-ARTERY-DISEASE; RANDOMIZED-TRIALS; UNRESTRICTED USE; METAANALYSIS; EFFICACY; CYPHER
Issue Date
201410
Publisher
ELSEVIER IRELAND LTD
Citation
INTERNATIONAL JOURNAL OF CARDIOLOGY, v.176, no.3, pp.583 - 588
Abstract
Background: In contrast to many studies comparing everolimus-eluting stent (EES) with paclitaxel-eluting stent (PES), data directly comparing EES with sirolimus-eluting stent (SES) are limited, especially in patients with acute myocardial infarction (AMI). Methods: This study includes 2911 AMI patients treated with SES (n = 1264) or EES (n = 1701) in Korea Acute Myocardial Infarction Registry (KAMIR). Propensity score matching was applied to adjust for baseline imbalance in clinical and angiographic characteristics, yielding a total of 2400 well-matched patients (1200 receiving SES and 1200 receiving EES). One-year clinical outcomes were compared between the two propensity score matched groups. Results: Baseline clinical and angiographic characteristics were similar between the two propensity score matched groups One-year clinical outcomes of the propensity score matched cohort were comparable between the EES versus the SES groups including the rates of cardiac death (4.8% vs. 4.8%, P = 1.000), recurrent myocardial infarction (1.4% vs. 1.7%, P = 0.619), target lesion revascularization (1.4% vs. 1.6%, P = 0.737), target lesion failure (7.0% vs. 7.3%, P = 0.752), and probable or definite stent thrombosis (0.5% vs. 0.9%, P = 0.224) except for a trend toward lower incidence of target vessel revascularization (1.9% vs. 3.0%, P = 0.087) and a lower rate of total major adverse cardiac events (9.3% vs. 11.9%, P = 0.034) in the EES group. Conclusions: The present propensity score matched analysis performed in a large-scale, prospective, multicenter registry suggests that the second-generation drug-eluting stent EES has at least comparable or even better safety and efficacy profiles as compared with SES in the setting of AMI. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
URI
http://hdl.handle.net/YU.REPOSITORY/30591http://dx.doi.org/10.1016/j.ijcard.2014.08.049
ISSN
0167-5273
Appears in Collections:
의과대학 > 내과학교실 > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE